J. Engel

Clusterin (CLU) is expressed in tissues and body fluids and is altered in some pathologies. In endometriosis, a noninvasive test is still lacking, thus, we analyzed CLU in mucus samples of patients. Additionally, we investigated localizatio…

Agonists of luteinizing hormone-releasing hormone (LHRH) induce a reversible hypoestrogenic state through the down-regulation of LHRH receptors and desensitization of the pituitary. Since endometrial implants are estrogen sensitive, LHRH ag…

Endometriose, d. h. das Vorhandensein von Gebärmutterschleimhaut außerhalb des Cavum uteri, ist eine Erkrankung, die ungefähr 10 % aller Frauen in der reproduktiven Lebensphase betrifft [1]. In den meisten Fällen befindet sich das ektope En…

OBJECTIVE: To illustrate pitfalls in the diagnosis of endometriosis and cervical cancer. DESIGN: Case report. SETTING: University hospital, department of obstetrics and gynecology. PATIENT(S): A 45-year-old woman with menorrhagia, pelvic…

BackgroundScreening is an unsolved problem for ovarian cancer (OvCA). As late detection is equivalent to poor prognosis, we analysed whether OvCA patients show diagnostically meaningful microRNA (miRNA) patterns in blood cells.MethodsBlood-…

This article reviews the clinical uses of agonists and antagonists of luteinizing-hormone-releasing hormone (LHRH), also known as gonadotropin-releasing hormone. In particular, the state of the art treatment of breast, ovarian and prostate …

In those clinical situations in which an immediate and profound suppression of gonadotrophins is desired, LHRH agonists have the disadvantage of producing an initial stimulatory effect on hormone secretion. Therefore, the use of GnRH antago…

Luteinizing hormone-releasing hormone (LHRH) plays a crucial role in controlling the ovarian cycle in women. By modification of the molecular structure of this decapeptide, analogues were synthesized with agonistic or antagonistic effects o…